Stocktoria
QIAGEN N.V. QGEN
NYSE · XNYS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1996-09-01
QIAGEN N.V. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.1B | $2.0B | $2.0B | $2.1B | $2.3B |
| Gross profit | $1.3B | $967.4M | $1.2B | $1.4B | $1.5B |
| Operating income | $465.9M | $97.7M | $409.9M | $531.5M | $630.1M |
| Interest expense | — | — | $53.4M | $58.4M | $54.5M |
| Income tax | $65.4M | $37.6M | $88.5M | $89.4M | $113.2M |
| Net income | $424.9M | $83.6M | $341.3M | $423.2M | $512.6M |
| EPS (diluted) | $1.94 | $0.37 | $1.48 | $1.84 | $2.21 |
| Operating cash flow | $654.3M | $673.6M | $459.5M | $715.3M | $639.0M |
| Free cash flow | $453.3M | $506.4M | $309.7M | $586.0M | $449.1M |
| Cash & equivalents | $839.0M | $663.6M | $668.1M | $730.7M | $880.5M |
| Inventory | $301.9M | $279.3M | $398.4M | $358.0M | $327.5M |
| Total assets | $6.3B | $5.7B | $6.1B | $6.3B | $6.1B |
| Shareholders' equity | $3.8B | $3.6B | $3.8B | $3.5B | $3.1B |
Source: SEC EDGAR filings · CIK 0001015820 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.